Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

18.216.229.154
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Dermatology

High-dose systemic minocycline most effective for treating papules and pustules in rosacea

Posted on

High-dose systemic minocycline is the most effective treatment option for rosacea patients with papules and pustules, with a low risk of adverse events (AEs), according to a study. However, more evidence-based data are needed to determine the impact of antibiotics on erythema.

Researchers analyzed all available randomized controlled trials (RCTs) related to rosacea therapy, including both published and unpublished research.

-Advertisement-
-Advertisement-

In total, 31 RCTs involving 8226 patients were included in the analysis. The trials demonstrated low heterogeneity and inconsistency, and all were considered to have a low risk of bias. The primary outcome evaluated was the improvement of the Investigator’s Global Assessment (IGA) scores, while secondary outcomes included the improvement of the Patient’s Global Assessment (PaGA) scores, Clinician’s Erythema Assessment (CEA) scores, and AEs.

Based on the findings, oral doxycycline 40 mg, minocycline 100 mg, minocycline 40 mg, as well as topical ivermectin and metronidazole 0.75%, were identified as effective treatments for reducing papules and pustules and improving IGA scores in rosacea patients. Among these, minocycline 100 mg was ranked the most effective. For improving PaGA scores, topical ivermectin, metronidazole 1%, and systemic oxytetracycline demonstrated efficacy, with oxytetracycline yielding the best results. However, neither doxycycline 40 mg nor metronidazole 0.75% showed therapeutic effects on erythema, a common symptom of rosacea.

In terms of safety, it was observed that systemic use of azithromycin and doxycycline 100 mg significantly increased the risk of adverse events.

The authors concluded that it is important to consider the specific phenotype of rosacea and balance the potential benefits and safety considerations when prescribing antibiotics to patients due to the risk of adverse events.

Reference
Xiao W, Chen M, Wang B, et al. Efficacy and safety of antibiotic agents in the treatment of rosacea: a systemic network meta-analysis. Front Pharmacol. 2023;14:1169916. doi: 10.3389/fphar.2023.1169916. PMID: 37251342; PMCID: PMC10210163.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-